Announcement PDF Annual Report 2025 I 2025 Annual Report II LOOKING TO THE FUTUR Strategic Growth, Driven by Clinical Need As global incidence of pancreatic cancer continues to rise, our mission becomes increasingly urgent—and increasingly valuable. Between 2025 and 2035, new case numbers of pancreatic cancer are projected to grow significantly across key European markets such as Germany (+12%), Spain (+19%), and Italy (+15%), while emerging regions like the Middle East & North Africa (‘MENA’) area are expected to show an even larger increase of +46%. These projections guide our expansion strategy: focusing on high- priority near-term markets while building pathways for long-term growth in high-potential geographies such as the United States, China, and Australia. III Projected Increase in Pancreatic Cancer Incidence (2025-2035) Japan Germany 0 10 20 30 40 50 France Italy United Kingdom Spain United States Australia China MENA 64,265 22,587 9,282 16,1 1 1 1 1,852 16,538 127,748 50,350 4,353 10,762 United States Germany Spain Italy United Kingdom France China Japan Australia MENA 77,446 25,264 1 1,062 18,449 13,934 19,072 170,188 53,129 5,540 15,750 Incidence (Estimated number of new cases in 2035) Incidence (Estimated number of new cases in 2025) Country Reference: International Agency for Research on Cancer. Cancer Tomorrow [Internet]. Lyon: IARC; 2020 [cited 2025 Jul 24]. Available from: https://gco.iarc.fr/tomorrow IV CLINICAL TRIAL UPDATE Clinical Advancement Fueling Strategic Expansion TRIPP-FFX Trial Update TRIPP-FFX, conducted across 15 sites, investigates OncoSil™ in addition to FOLFIRINOX chemotherapy. With recruitment completed soon after end-FY25, the trial supports potential label expansion—broadening treatment options and accelerating market uptake. These trials underpin our commitment to transforming pancreatic cancer care and expanding our commercial footprint. Our ongoing clinical trials are key to expanding OncoSil™’s potential and accelerating its adoption worldwide. V An open-label, multi-centre, randomised study of TaRgeted Intratumoural Placement of Phosphorous-32 (OncoSil™) in addition to FOLFIRINOX chemotherapy versus FOLFIRINOX chemotherapy alone in patients with unresectable locally advanced pancreatic adenocarcinoma. TRIPP-FFX *in July 2025 Objective To assess the safety and efficacy of OncoSil™ when given in addition to standard FOLFIRINOX chemotherapy for treatment of locally advanced pancreatic cancer. Primary Endpoint • Safety and tolerability as determined by the adverse event profile • Local disease control rate at 16 weeks Location and Status • 15 sites across Spain, UK, Belgium, Australia and Italy • Recruitment completed* Commercial Impact Accelerates market penetration with label expansion to include use of OncoSil™ device in addition to FOLFIRINOX chemotherapy VI CLINICAL TRIAL UPDATE Clinical Advancement Fueling Strategic Expansion PANCOSIL (Investigator-Initiated Study) Trial Update PANCOSIL, initiated by Amsterdam UMC, explores a novel delivery method via Interventional Radiology—introducing OncoSil™ to a new medical specialty. With recruitment completed soon after end-FY25, this trial aims to lower adoption barriers and drive faster market entry. VII Safety and feasibility of CT-guided percutaneous radionuclide therapy (RNT) with the OncoSil™ device in patients with non-progressive locally advanced pancreatic cancer (PANCOSIL): an open-label, single-arm phase 1-2 feasibility study. PANCOSIL (Investigator-Initiated Study) *in July 2025 Objective To assess the safety and feasibility of percutaneous CT or ultrasound-guided RNT using the OncoSil™ device in patients with non-progressive locally advanced pancreatic cancer after induction chemotherapy treatment. Primary Endpoint Safety and feasibility of percutaneous RNT using the OncoSil™ device defined by the percentage of device- or procedure-related adverse events (> grade 3) until 90 days post-procedure. Location and Status • Amsterdam UMC, The Netherlands • Recruitment completed* Commercial Impact Accelerates market penetration with lower barriers to adoption via a new method of delivery for a new medical speciality (Interventional Radiology) VIII SITE TRAINING UPDAT Empowering Clinical Readiness Across Regions As OncoSil™ continues to expand across new territories, structured site training is essential to ensure clinical excellence and consistent treatment delivery. Over the past year, we have made significant progress, with training programs launched or completed in key markets including Spain, Italy, Turkey and Germany. Several countries now have fully trained and ready-to-activate sites, while others have already begun treating patients with OncoSil™. This growing network of trained centres not only demonstrates increasing adoption in clinical settings, but also accelerates our path to broader commercial availability. IX Türkiye Italy Germany Belgium Israel Austria Greece Netherlands Spain Portugual United Kingdom 2 3 3 5 4 2 3 2 10 13 1 1 2 15 11 1 4 3 1 Training Commenced Training Completed and ready to start Sites using OncoSil™ X FY25 HIGHLIGHT A Year of Momentum and Milestones FY25 marked a period of exceptional progress and validation for OncoSil Medical. From significant regulatory approvals across Europe to pivotal clinical trial recruitment milestones, the year was defined by acceleration on every front. Key comparative analysis further reinforced the clinical value of OncoSil™ in the treatment of pancreatic cancer, highlighting its superiority over conventional therapies. At the same time, OncoSil Medical expanded its global footprint through new distribution agreements and successfully raised capital to fuel continued growth. These achievements collectively strengthen OncoSil Medical’s position as an innovative leader in interventional oncology. January 2025: Lel Smits appointed as Non-Executive Director XI September 2024: First Comparative Analysis Indicates Significant Benefits from Adding OncoSil™ to Chemotherapy for Pancreatic Cancer May 2025: Comparative Analysis Reports Superiority of OncoSil™ Over Stereotactic Body Radiation Therapy in Patients with Pancreatic Cancer January 2025: MDR Approval Received from BSI November 2024: OncoSil Medical Signs Distribution Agreements for Nordics and Egypt October 2024: Distribution Agreement signed for the GCC Region October 2024: UKCA Renewal Certificates Without Post-Market Restrictions received October 2024: G-BA Approval Received for OncoSil™ Device in Germany October 2024: OncoSil Medical successfully completes a $7 million Placement June 2025: 99% recruitment achieved in TRIPP-FFX trial, 95% recruitment achieved in PANCOSIL study.* May 2025: OncoSil Medical announces $8.7m Capital Raise, completed over June and July 2025 XII *Recruitment for both studies have completed in July 2025. PATIENT & PHYSICIAN INTERVIEW Voices from the Frontline of Care At the heart of OncoSil Medical’s mission are the patients we serve and the dedicated physicians who guide their journey. In this section, we present first-hand perspectives from both physicians and patients—stories that illuminate resilience, renewed hope, and the meaningful clinical impact of this innovative treatment.These perspectives offer a powerful glimpse into the real-world difference OncoSil Medical is making in the fight against pancreatic cancer, reflecting the profound human and medical significance behind every case. XIII Patient Story: Antonia Pineiro Finding Strength, Hope, and Healing Through OncoSil™ Having the opportunity to have all this treatment made me hopeful and proud that all of this happened to me. Antonia Pineiro’s journey with pancreatic cancer is one marked by resilience, courage, and optimism. When offered OncoSil™ treatment, she embraced it with optimism. “I felt happy because I hoped that this treatment would help improve my situation going forward,” she recalls. Despite the challenges of chemotherapy, Antonia experienced no noticeable side effects from OncoSil™ and gradually returned to everyday activities. More than her own recovery, she focused on supporting her family: “It affected my family a lot, especially my daughter. I had to support them. Because if I collapse, they collapse. So we had to keep moving forward together.” Today, Antonia feels stronger and encourages others to consider this treatment. It affected my family a lot, especially my daughter. I had to support them. Because if I collapse, they collapse. So we had to keep moving forward together. XIV PATIENT & PHYSICIAN INTERVIEW Dr. José Lariño Noia Department of Gastroenterology at the University Hospital of Santiago de Compostela Dr. José Lariño Noia, who has extensive experience in managing pancreatic cancer patients, emphasizes the urgency and severity of the disease, and the profound impact that innovative treatments like OncoSil™ can have on both patients and care teams. He highlights the therapy’s potential not only to improve survival outcomes but also to convert previously inoperable tumors into surgical candidates. Most importantly, he underscores the value of offering patients a tangible path forward in the face of a difficult diagnosis. Pancreatic cancer is devastating. Anything that offers hope that can improve survival and make a tumour operable is a significant advance. What truly excites me about the OncoSil™ procedure is that we’re not just delivering treatment, we’re giving patients real hope, and the possibility of a better outcome. Their gratitude is priceless. XV Dr. Virginia Pubul Núñez Nuclear Medicine physician and Head of the Nuclear Medicine Department at the University Hospital of Santiago de Compostela OncoSil™ treatment is a fantastic new opportunity for pancreatic cancer patients who have very few treatment options. Dr. Virginia Pubul Núñez plays a central role in the multidisciplinary process of administering OncoSil™ treatment for patients with pancreatic cancer. Each patient is carefully reviewed by a multidisciplinary committee of specialists from Medical Oncology, Gastroenterology, Surgery, and Nuclear Medicine to determine suitability. Following the committee’s decision, Dr. Pubul Núñez and her team guide patients through the procedure, from diagnostic imaging and tumor sizing to the intratumoral implantation of the OncoSil™ device under endoscopic ultrasound guidance. Post-procedure, a SPECT-CT scan is performed to confirm accurate placement by detecting the Bremstrahlung radiation from Phosphorus-32. This is a highly coordinated, multidisciplinary procedure that allows us to personalise care with precision. We see promising results in terms of local tumor control and quality of life, which gives our patients a real reason to hope. XVI 1 Corporate directory Chair’s letter CEO’s report Directors’ report Auditor’s independence declaration Statement of profit or loss and other comprehensive income Statement of financial position Statement of changes in equity Statement of cash flows Notes to the financial statements Consolidated entity disclosure statement Directors’ declaration Independent auditor’s report to the members of OncoSil Medical Ltd Shareholder information 2 3 5 7 24 25 26 27 28 29 55 56 57 61 CONTENTS 2 Directors Mr Douglas Cubbin - Chairman Mr Nigel Lange Ms Lel Smits Dr Thomas Duthy Company secretary Ms Olga Smejkalova Notice of annual general meeting The details of the annual general meeting of OncoSil Medical Ltd are: 1 1:00 am (AEDT) Wednesday 19 November 2025 The offices of K & L Gates, Level 25, 525 Collins Street, Melbourne, Victoria Registered office Level 3 62 Lygon Street Carlton South, Victoria 3053 Phone: +61 2 8935 9629 Principal place of business Level 5 7 Eden Park Drive Macquarie Park, NSW 21 13 Phone: +61 2 8935 9629 Share register Boardroom Pty Limited Level 8 210 George Street Sydney NSW 2000 Phone: +61 2 9290 9600 Auditor Crowe Sydney Level 24 1 O’Connell Street Sydney NSW 2000 Solicitors K&L Gates Level 25, South Tower 525 Collins Street Melbourne VIC 3000 Bankers National Australia Bank 330 Collins Street Melbourne VIC 3000 Stock exchange listing OncoSil Medical Ltd shares are listed on the Australian Securities Exchange (ASX code: OSL) Website www.oncosil.com Corporate Governance Statement OncoSil Medical Ltd and the Board of Directors are committed to achieving and demonstrating the highest standards of corporate governance. OncoSil Medical Ltd has reviewed its corporate governance practices against the Corporate Governance Principles and Recommendations (4th Edition) published by the ASX Corporate Governance Council. Details of the corporate governance report is available on the Group website at: https://www.oncosil.com/investors 3 DIRECTORS’ REPORT ONCOSIL MEDICAL LTD 30 JUNE 2025 CHAIR’S LETTER restrictions, significantly simplifying commercial treatment initiation in the EU and UK, accelerating our market access capabilities and shortening sales cycles. Clinical and Commercial Expansion Our global footprint continues to strengthen. Notably: • The PANCOSIL and TRIPP-FFX clinical trials achieved 95% and 99% recruitment respectively by the end of June 2025. Both trials went on to complete recruitment in July 2025. • Our OncoSil™ device has been deployed in more than 30 treatments in Spain. • We signed distribution agreements serving Egypt, the Gulf Cooperation Council (GCC) countries (which includes the United Arab Emirates (UAE), Qatar, Oman, and Bahrain), and the Nordic countries (Sweden, Denmark, Norway, and Finland), expanding our market reach. • During the third quarter of FY2025, OncoSil Medical received a $1,050,896 R&D tax incentive, bolstering our capital for continued innovation in targeted radiotherapy. • Furthermore, at Digestive Disease Week 2025 (3 – 6 May 2025, San Diego), investigators from the Royal Adelaide Hospital presented a comparative study demonstrating superior outcomes of OncoSil™ over SBRT (stereotactic body radiation therapy) in patients with locally advanced pancreatic cancer – improved median overall survival (22 months vs. 14 months), extended progression-free survival, and a favourable safety profile. Capital Consolidation In June 2025, shareholders approved – and we completed – a 1-for-400 consolidation of the Company’s issued capital. Douglas Cubbin Non-executive Chairman OncoSil Medical Dear Shareholders, I am pleased to present OncoSil Medical’s Annual Report for the fiscal year ended 30 June 2025. This period has been transformational for our company, marked by strong operational progress and significant corporate developments. Regulatory and Market Access Achievements In late January 2025, we secured Medical Device Regulation (MDR) certification for the OncoSil™ device from BSI, the EU Notified Body. This pivotal approval removes prior post-market 4 This has streamlined our capital structure and positioned us for stronger market engagement and investor clarity. Australian institution invested $2.7 million through placement As announced on 25 July 2024, OncoSil completed a placement with Pengana Capital Group for $2.7 million before costs via the issue of approximately (on a pre-capital consolidation basis) 386 million new fully paid ordinary shares in the Company (New Shares) at $0.007 per New Share (Offer Price) together with one OSLOB Short Dated Listed Option (expiry date 30 June 2025, exercise price $0.009 each) (New Options) for each New Share issued under the Placement. Robust Capital Raises We completed a $8.0 million capital raise through a placement of $7.0 million in November 2024 and a $1 million Share Purchase Plan (SPP) in December 2024. The funds were applied to further investment in OncoSil’s Macquarie Park manufacturing facility, funding of clinical trials, and other working capital costs and costs of the offer. We successfully executed an $8.7 million capital raise, comprising a $6.7 million placement and a $2 million SPP. Tranche 1 of the placement ($3.2 million) completed in June 2025 and Tranche 2 of the placement ($3.5 million) and the $2 million SPP completed in July 2025. The raise was backed by both new and existing institutional investors, with Pengana Capital Group playing a cornerstone role. These funds raised will primarily support the commercialisation of our OncoSil™ device across Europe and our existing territories. Governance and Board Strengthening In January 2025, we welcomed Ms. Lel Smits to the Board as a Non-Executive Director. With deep expertise in n corporate communications, governance, and strategic engagement from advising over 500 ASX listed entities, Ms Smits strengthens our leadership team as we scale our operations. Shortly after the end of the financial year, on 1 1 July 2025 we announced the appointment of Dr Thomas Duthy as a Non-Executive Director. He brings more than 21 years of experience across financial markets, corporate development, and board-level roles in the healthcare and life sciences sectors. Dr Duthy is the Founder and Director of Nemean Group, a corporate advisory firm serving healthcare and technology companies, has been involved in numerous successful M&A transactions and holds relevant experience in the oncology device setting, given his previous role as Head of Corporate Development and Investor Relations at Sirtex Medical (ASX:SRX), where he played a key role in its $1.9 billion acquisition. In conjunction with Dr Duthy’s appointment, Dr Gabriel Liberatore resigned from the OncoSil Board of Directors for personal reasons, effective 1 1 July 2025. The Board extends its sincere thanks to Dr Liberatore for his valuable contribution and dedicated service to OncoSil Medical. Looking Ahead As we move into FY26, OncoSil is well-positioned to deliver on its mission. We remain focussed on expanding commercial adoption of our device, completing our key clinical trials, and pursuing new market opportunities. With a strengthened capital position and a dedicated team, we are confident in our ability to build on the foundation laid this year. To our shareholders, thank you for your continued support and belief in our vision. Together, we are progressing toward a future where OncoSil™ becomes a meaningful part of the global fight against pancreatic cancer. Douglas Cubbin Non-executive Chairman OncoSil Medical 5 DIRECTORS’ REPORT ONCOSIL MEDICAL LTD 30 JUNE 2025 CEO’S REPORT A key highlight of the year was the approval from German Federal Joint Committee (Gemeinsamer Bundesausschuss, G-BA) for the clinical trial in Germany. This is one of the most significant achievements in OncoSil’s history. The G-BA is Germany’s highest decision-making body for healthcare reimbursement, and this approval and successful completion of the clinical trial will broaden access to the OncoSil™ device across the German public hospital system. A successful completion of the clinical trial paves the way for further reimbursement negotiations in other EU member states and beyond, as the G-BA decision is often referenced by peer health systems. It also validates the clinical strength of our data and positions the OncoSil™ device as a credible and scalable cancer therapy option in one of the world’s most advanced healthcare environments. In parallel, we have seen a sharp increase in German hospital applications for NUB (Neue Untersuchungs- und Behandlungsmethoden) approvals, which rose by over 40% year-on-year. NUB is a hospital-led process to secure temporary, hospital-specific extra reimbursement for new inpatient treatments. This approval serves to unlock access to funding in Europe’s largest market. Another major regulatory milestone was achieving certification under the EU MDR framework. The MDR represents one of the most stringent and comprehensive medical device regulatory regimes globally. Achieving certification under this standard is a rigorous process that speaks to the safety, quality, and clinical robustness of our product. Importantly, MDR approval ensures our continued access to EU markets beyond the legacy MDD (Medical Device Directive) certification and removes previous restrictions on post- Mr Nigel Lange Chief Executive Officer & Managing Director OncoSil Medical Dear Shareholders, I am pleased to present OncoSil Medical Ltd’s CEO Report for the financial year ended 30 June 2025—a year in which we delivered meaningful progress toward our mission of improving outcomes for patients with pancreatic cancer. This year was defined by strong clinical momentum, an exceptional regulatory breakthrough in Germany, and the continued commercialisation of our innovative brachytherapy device across key global markets. 6 market commercialisation. This certification reinforces OncoSil’s position as a trusted device manufacturer and provides a strong foundation for long-term growth across Europe and the UK. In parallel, we have made substantial progress in our clinical development program. Recruitment in both our TRIPP FFX and PANCOSIL studies surpassed the >90% recruitment at the end of FY25 (both studies were completed in July 2025), a significant achievement that reflects strong clinical interest and institutional confidence in our therapy. These trials are essential to our long-term strategy. TRIPP-FFX study is designed to generate high-quality evidence on the efficacy and safety of OncoSil™ when used in combination with standard-of-care chemotherapy (FOLFIRINOX). PANCOSIL study evaluates the safety and feasibility of CT-guided percutaneous implantation of OncoSilTM device. The data from these studies will not only support further regulatory engagement with additions to our existing labelling but also strengthen our case for reimbursement and clinical expansion in new and existing markets. From a commercial perspective, FY25 marked our strongest sales performance to date. Dose sales increased by 100% year-on-year, contributing to an 83% increase in full-year sales and a 127% uplift in revenue compared to the prior year. Pricing has remained consistent throughout the year. Approximately 60% of revenue was generated by direct sales while the remaining 40% was distributor generated. These results were driven by growing demand across the Europe, particularly in Spain, Greece and Israel, reflecting both the maturing of our commercial model and the accelerating recognition of our technology in clinical practice. We also broadenedourgeographicreach,securingdistribution agreements across the Nordic region, Egypt, and the Gulf countries ensuring that more patients worldwide will have access to our device. To support these growth initiatives, we took proactive steps to strengthen our balance sheet. Over the course of the year, we completed capital raises totalling more than $14 million, including a successful institutional placement and share purchase plans. These funds have extended our operational runway into FY26 and will enable us to continue investing in clinical trials, market development, and regulatory engagement. We also received a $1.05 million R&D tax refund, which reflects our continued commitment to innovation and evidence-based medicine. In support of our longer-term manufacturing and operational strategy, we also made important progress on the development of our Macquarie Park manufacturing facility in Sydney. The facility is being prepared as a dedicated site to produce the OncoSil™ device and is designed to meet the rigorous quality standards required for global regulatory approvals. Once operational, the Macquarie Park facility will enhance our control over production, improve scalability, and support the transition toward in-house manufacturing, thereby strengthening supply chain security and cost efficiency over time. As we look ahead to FY26, our priorities are clear. We will continue driving adoption in key existing markets, launch in new countries, and place a strong emphasis on accelerating sales growth and maximising revenue. With the major regulatory barriers now behind us and growing clinical endorsement ahead of us, we believe we are at a genuine inflection point in our journey. In closing, I would like to thank our shareholders for your ongoing support and trust. The progress we have made over the past year reflects the resilience and dedication of our team, the strength of our technology, and the clarity of our mission. We remain committed to improving the lives of patients living with pancreatic cancer and to delivering long-term, sustainable value to you—our shareholders. Nigel Lange Chief Executive Officer & Managing Director OncoSil Medical 7 DIRECTORS’ REPORT ONCOSIL MEDICAL LTD 30 JUNE 2025 The directors present their report, together with the financial statements, on the consolidated entity (referred to hereafter as the ‘Group’) consisting of OncoSil Medical Ltd (referred to hereafter as the ‘Company’ or ‘parent entity’) and the entities it controlled at the end of, or during, the year ended 30 June 2025. Directors The following persons were directors of OncoSil Medical Ltd during the whole of the financial year and up to the date of this report, unless otherwise stated: Mr Douglas Cubbin Independent Non-Executive Chairman Mr Nigel Lange Chief Executive Officer and Managing Director Ms Lel Smits Independent Non-Executive Director (appointed 15 January 2025) Dr Thomas Duthy Independent Non-Executive Director (appointed on 1 1 July 2025) Dr Gabriel Liberatore Independent Non-Executive Director (resigned on 1 1 July 2025) Information on directors Name MR DOUGLAS CUBBIN Title Non-Executive Director and Chairman Qualifications BBus., FCPA, GAICD Experience and expertise Mr Cubbin is an experienced biopharmaceutical executive with over 31 years’ experience in senior executive, CFO, Director and Chair roles, across varied industries. During his tenure as Group Chief Financial Officer at Telix Pharmaceuticals Limited (ASX:TLX), a global biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic radiopharmaceuticals, he was a key member of the team which successfully completed the IPO, raised $270 million in capital and grew the business to a multi-billion dollar market capitalisation. Mr Cubbin has also served as Chairman of various boards, including Australian Nuclear Science and Technology Organisation (ANSTO) Nuclear Medicine. Other current directorships None Former directorships (last 3 years) None Special responsibilities Member of the Nomination and Remuneration Committee and member of Audit and Risk Committee Interests in shares 62,000 ordinary shares (Owned by related party) Interests in options 12,500 options 18,750 listed options (Owned by related party) 25,000 unlisted options (Owned by related party) Name MR NIGEL LANGE Title Chief Executive Officer and Managing Director Qualifications BA, B.Comm Experience and expertise Nigel joined the Company in May 2020 as Europe, Middle East and Africa (‘EMEA’) President and brings with him over 31 years of experience in the medical devices industry. Since 2003, Nigel has held various leadership roles with Sirtex Medical, a global leader in brachytherapy treatment for liver cancer. From 2003, Nigel served as Chief Executive Officer of Sirtex’s European business, responsible for establishing their brachytherapy device in over 300 centres across Europe and the Middle East. Since 2017, Nigel served as Group Chief Commercial Officer where he was responsible for all commercial aspects of the global business. During this time, Nigel has also held interim roles including Interim Group CEO and Interim CEO of Asia Pacific. Other current directorships None Former directorships (last 3 years) None Special responsibilities Member of the Nomination and Remuneration Committee and member of Audit and Risk Committee Interests in shares 3,750 ordinary shares 14,296 performance dependent loan shares Interests in options 2,500 listed options Interests in rights 242,030 performance rights 8 Name MS LEL SMITS Title Non-Executive Director (appointed on 15 January 2025) Qualifications Graduate of Australian Institute of Company Directors’ (AICD) Company Directors Course, has secured a Diploma of Investor Relations from Australasian Investor Relations Association (AIRA) and a Master of Arts in Journalism from University of Technology, Sydney (UTS). Experience and expertise Lel Smits is an award-winning entrepreneur, director and leader with a significant track record advising more than 500 ASX-listed management teams and Boards and serving as a Director on Australian Shareholders’ Association since 2021. Lel was awarded Director of the Year by Women in Finance in 2024 and 2022 and Communications and Marketing Professional of the Year by Women in Wealth in 2025. Commencing her career as a journalist, Lel gained extensive global financial markets experience through producing and presenting thousands of finance reports and CEO interviews as a broadcast finance journalist in Australia and as a New York foreign correspondent for the Australian Financial Review, reporting from Wall Street, U.S.A. Extensive ASX listed company experience and formal education foundations propelled Lel to advise and contribute to more entrepreneurial ventures and boards through governance, strategy and risk oversight and marketing, brand, communications and corporate affairs. Lel is currently a Director of Australian Shareholders’ Association. Other current directorships None Former directorships (last 3 years) None Special responsibilities Member of Audit and Risk Committee. Interests in shares None Interests in options 7,500 options Name DR THOMAS DUTHY Title Non-Executive Director (appointed on 1 1 July 2025) Qualifications Dr Duthy holds a PhD from the University of Adelaide and an MBA from Deakin University. E